Understand the source comparison
BDNF Neuroplasticity Nootropic Peptides: Mechanism Comparison
Cerebrolysin Mimics neurotrophic factor activity (NGF/BDNF fragments) Yes. Receptor-mediated transcytosis 10–30ml IV over 10–20 days Phase III trials in dementia (published JNEUROTRANS) Strongest clinical evidence for cognitive improvement in neurodegeneration
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- Mimics neurotrophic factor activity (NGF/BDNF fragments)
- Yes. Receptor-mediated transcytosis
- 10–30ml IV over 10–20 days
- Phase III trials in dementia (published JNEUROTRANS)
- Strongest clinical evidence for cognitive improvement in neurodegeneration
- Dihexa
- HGF receptor (c-Met) activation → dendritic growth
- Yes. Small molecule crosses passively
- 0.5–2mg/kg subcutaneous
- Preclinical only (rodent models, PLOS ONE)
- Highest potency for synaptogenesis, but no human trials yet
- P21
- Enhances CREB transcriptional activity → BDNF upregulation
- Yes. Intranasal delivery bypasses barrier
- 1–5mg intranasal
- Preclinical + limited human observational data
- Requires intranasal administration; oral forms ineffective
- Semax
- ACTH(4-10) analog → increases BDNF mRNA expression
- Partial. Intranasal penetration documented
- 300–600mcg intranasal
- Phase II trials in stroke recovery (Russia)
- Primarily studied for neuroprotection, not cognition enhancement
- NSI-189
- Stimulates hippocampal neurogenesis via unknown pathway
- Unknown. Presumed partial
- 40mg oral (human trials)
- Phase II for major depressive disorder
- Cognitive effects secondary to antidepressant action